Fort Washington Investment Advisors Inc. OH Purchases 53,617 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Fort Washington Investment Advisors Inc. OH lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 376,047 shares of the biopharmaceutical company's stock after acquiring an additional 53,617 shares during the quarter. Fort Washington Investment Advisors Inc. OH's holdings in Gilead Sciences were worth $34,735,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Bellevue Group AG boosted its stake in shares of Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock worth $3,859,000 after buying an additional 7,093 shares during the last quarter. Quantinno Capital Management LP increased its holdings in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock worth $6,843,000 after purchasing an additional 48,910 shares during the period. Legal & General Group Plc raised its position in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC purchased a new stake in Gilead Sciences during the third quarter valued at about $830,000. Finally, Capital Investment Advisors LLC increased its holdings in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after buying an additional 9,791 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Truist Financial boosted their price target on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research report on Friday, November 8th. Morgan Stanley upgraded shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Robert W. Baird boosted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Finally, Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $97.96.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.29% of the company's stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $0.57 during mid-day trading on Wednesday, reaching $92.39. The company's stock had a trading volume of 1,829,414 shares, compared to its average volume of 6,645,859. The firm has a market cap of $115.14 billion, a price-to-earnings ratio of 1,026.20, a PEG ratio of 1.29 and a beta of 0.18. The business has a 50 day moving average price of $91.62 and a 200-day moving average price of $84.57. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.33%. The ex-dividend date was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.